



iTrack™ MIGS Device Featured in Instructional Training Course at Sydney Eye Hospital, Australia

Fremont, California, 3 November 2020 – Nova Eye Medical Limited, a medical technology company committed to advanced ophthalmic treatment technologies and devices, is pleased to report that its proprietary iTrack™ minimally invasive glaucoma surgery (MIGS) device was showcased during the annual MIGS Course at Sydney Eye Hospital over the weekend, one of Australia’s preeminent teaching universities.

Hosted since 2017, the one-day MIGS Course was developed by Drs. Colin Clement (NSW) and Frank Howes (QLD) to enable Australian physicians to develop and practice surgical skills and capabilities across a number of MIGS treatment options, with specific wet-lab/dry-lab and hands-on training.

The iTrack™ canaloplasty microcatheter device figured alongside the iStent® microstent (Glaukos) and Hydrus® microstent (Ivantis).

Associate Professor Dr. Ashish Agar, President of the Australian Society of Ophthalmologists (ASO), presented surgical pearls and clinical tips for the iTrack™ canaloplasty microcatheter device during the MIGS Course. According to Dr. Agar, the Course provides needed teaching exposure to MIGS devices and technologies.

“It’s great that the registrars at Sydney Eye Hospital are able to get exposure to these devices and procedures through this course, which they aren’t usually exposed to in their regular training,” said Dr. Agar.

According to Tom Spurling, Director of Nova Eye Medical, the Company will look to materially grow the presence of iTrack™ in the Australian market over the coming years and to support the clinical work of its growing network of iTrack™ physicians. iTrack™ has been registered in Australia by the Therapeutic Goods Administration since June 2015 but is not yet reimbursed via the Australia Private Health Insurance Prosthesis List.

“iTrack™ has proven itself to be important in the glaucoma treatment algorithm in global markets, and we anticipate the same for the Australian market. We look forward to partnering with leading glaucoma surgeons in Australia to drive procedural adoption of iTrack™ and to support its use in clinical practice,” said Mr. Spurling.



ABOUT iTRACK™

The iTrack™ is an atraumatic, tissue sparing glaucoma surgery that achieves excellent clinical outcomes while also preserving the viability of subsequent glaucoma treatments. Based on the same principles of angioplasty, iTrack™ combines 360-degree catheterization with viscodilation to mechanically remove blockages and to dilate Schlemm's canal in order to remove outflow resistance. Performed via an ab-interno approach, iTrack™ is redefining the treatment of mild-moderate glaucoma, achieving excellent clinical outcomes while preserving future treatment options. It can also be performed via an ab-externo approach as a bleb-free alternative to trabeculectomy.

For additional information about Nova Eye Medical and its technologies, please visit: www.glaucoma-iTrack.com

ABOUT NOVA EYE MEDICAL

Nova Eye Medical Limited is a medical technology company that develops, manufactures and sells a portfolio of proprietary ophthalmic treatment technologies and devices. Used by eye surgeons in more than 100 countries globally, these technologies include iTrack™ minimally invasive glaucoma surgery (MIGS), a consumable surgical device that restores the eye's natural outflow pathway to lower pressure inside the eye and to eliminate patient reliance on anti-glaucoma medications for mild-moderate glaucoma. The Molteno3® glaucoma drainage device is designed to enhance surgical utility and optimize clinical outcomes for long-term IOP control in cases of severe glaucoma. It also offers the benefit of a simplified and faster surgical profile. With its sales headquarters based in Fremont, California, Nova Eye Medical is supported by offices in Adelaide, Australia and Berlin, Germany, and a global network of more than 50 distribution partners. Manufacturing facilities are located in Fremont, California and Dunedin, New Zealand.

For additional information about Nova Eye Medical and its technologies, please visit: www.nova-eye.com



Media enquires:

Kate Hunt

Nova Eye Medical Limited

W +61 404 080 679

khunt@nova-eye.com

Investor enquires:

Dr. Tom Duthy

Nova Eye Medical Limited

W +61 402 493 727

tduthy@nova-eye.com